Q4 2024 IDEXX Laboratories Inc Earnings Call Transcript
Key Points
- IDEXX Laboratories Inc (IDXX) reported a 6% organic revenue growth in Q4 2024, with CAG Diagnostic recurring revenues increasing by 7% organically.
- The company achieved a full-year EPS of $10.67 per share, marking a 12% increase on a comparable basis.
- IDEXX's international CAG Diagnostic recurring revenue growth was strong at 12% in Q4, supported by net price gains and improved volume growth.
- The company successfully launched IDEXX inVue Dx, a new cellular analyzer, with nearly 1,600 preorders globally by the end of Q4.
- IDEXX's software business saw double-digit growth in cloud-native PIMS placements, enhancing clinic efficiency and fostering deeper connections with practices and pet owners.
- US same-store clinical visit levels declined nearly 3% in Q4 and 2% for the full year in 2024, posing a constraint on IDEXX's growth.
- Rapid assay revenue was flat on an organic basis in Q4, constrained by pressure on US wellness visits.
- Operating expenses increased by 10% as reported in Q4, reflecting higher R&D spending.
- Foreign exchange had a negative impact on Q4 EPS, contributing to a $0.03 per share headwind.
- The company faces a 2% negative impact on full-year 2025 revenue growth due to foreign exchange rates.
Good morning, and welcome to the IDEXX Laboratories fourth quarter 2024 earnings conference call. As a reminder, today's conference is being recorded.
Participating in the call this morning are Jay Mazelsky, President and Chief Executive Officer; Brian McKeon, Chief Financial Officer; Andrew Emerson, Senior Vice President, Corporate and Companion Animal Group Finance; and John Ravis, Vice President, Investor Relations.
IDEXX would like to preface the discussion today with a caution regarding forward-looking statements. Listeners are reminded that our discussion during the call will include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today.
Additional information regarding these risks and uncertainties is available under the forward-looking statements noticed in our press release issued this morning as well as in our periodic filings with the Securities and Exchange Commission, which can be obtained from the SEC or by visiting the Investor Relations section of our website, idexx
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
